NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML
rawpixel / Pixabay

NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML

  In an early February press release, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that XOSPATA (gilteritinib) was given conditional approval in China for the treatment of patients with FLT3-mutated…

Continue Reading NMPA Grants Conditional Approval to XOSPATA for FLT3mut+ AML
International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
source: pixabay.com

International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers

  COVID-19 has now taken hold in over one hundred eighty countries. According to a recent article in The Lancet, in May of 2020, the United States reported the highest…

Continue Reading International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
From “Survivor” to Surviving Hodgkin Lymphoma: How Ethan Zohn’s Log Challenge Raises Cancer Awareness
Photo by Thomas Peham on Unsplash

From “Survivor” to Surviving Hodgkin Lymphoma: How Ethan Zohn’s Log Challenge Raises Cancer Awareness

  Growing up, my family and I faithfully watched Survivor each week. Although my parents stopped watching a few years back, settling in every Wednesday during the season is somewhat of a…

Continue Reading From “Survivor” to Surviving Hodgkin Lymphoma: How Ethan Zohn’s Log Challenge Raises Cancer Awareness

Acute Lymphoblastic Leukemia: Miracles for Millions and the People Who Created Them

  According to a recent article in MedicalXpress, the story begins fifty years ago with the grim statistics that a child with acute lymphoblastic leukemia (ALL) would not survive longer than…

Continue Reading Acute Lymphoblastic Leukemia: Miracles for Millions and the People Who Created Them

How Changing to Outcome-Based Reimbursement Models is Better for Rare Disease Patients

Shifting Contracts Over the years the United States healthcare system has shifted more toward reimbursement models that are outcome-based instead of service-based. In essence, this means that instead of paying…

Continue Reading How Changing to Outcome-Based Reimbursement Models is Better for Rare Disease Patients